An investigation on behalf of investors in BioScrip Inc (NASDAQ:BIOS) shares over potential wrongdoing at BioScrip was announced and NASDAQ:BIOS stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 01/27/2015 --An investigation on behalf of current long-term investors in NASDAQ:BIOS shares was announced concerning possible breaches of fiduciary duties by certain BioScrip officers and directors.

Investors who purchased shares of BioScrip Inc (NASDAQ:BIOS) and currently hold any of those NASDAQ:BIOS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain BioScrip officers and directors breached their fiduciary duties and caused damage to the company and NASDAQ:BIOS shareholders.

On September 23, 2013, BioScrip Inc disclosed that the Company received a civil investigative demand issued by the United States Attorney's Office for the Southern District of New York and a subpoena from the New York State Attorney General's Medicaid Fraud Control Unit, regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade(R) by the Company's legacy specialty pharmacy division.

On September 30, 2013, a lawsuit was filed against BioScrip over alleged Securities Laws Violations. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that BioScrip Inc improperly distributed the product Exjade through its specialty pharmacy operations, that BioScrip Inc was in violation of certain federal and state laws and regulations, and that as a result of the foregoing BioScrip's statements were materially false and misleading at all relevant times.

BioScrip Inc reported that its annual Total Revenue rose from $662.64 million in 2012 to $842.20 million in 2013 while its Net Income of $64.71 million in 2012 declined to a Net Loss of $69.65 million in 2013. Shares of BioScrip Inc (NASDAQ:BIOS) declined from $16.55 per share in August 2013 to as low as $5.69 per share in November 2014.

On January 23, 2015, NASDAQ:BIOS shares closed at $5.92 per share.

Those who purchased shares of BioScrip Inc (NASDAQ:BIOS), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.